Homepage Top Section1

SBT-77-7101 is described as an autologous CAR-Treg cell therapy currently in Phase I clinical development to treat patients with poly-refractory rheumatoid arthritis (RA). These patients with RA have

The new approvals for the anti-programmed death-1 (PD-1) therapies cover both neoadjuvant (pre-surgery) and adjuvant (post-surgery) treatment and apply to patients regardless of their eligibility for cisplatin. These

The company signed the agreement to test the investigational therapy with Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Human Genome

Facilitated by Ramot, which manages technology transfer for Tel Aviv University, the agreement will combine computational and experimental tools for academic teams and scientific entrepreneurs seeking to advance

The deal includes an upfront payment of $1.1bn and up to $400m in potential milestone payments. It is expected to close in the second half of 2026, pending

The deal includes a strategic equity investment by AimedBio in Inocras and a joint research agreement between the two companies. Additionally, the whole genome sequencing (WGS) capabilities of

Nuvectis secured worldwide rights, outside specified Asian territories, to develop, manufacture and commercialise Haisco’s drug candidates HSK42360 and HSK39297. Haisco will receive $40m in upfront and near-term payments,

Executives from both organisations, including LG AI Research head Woohyung Lim and D&D Pharmatech CEO Seulki Lee, attended the event to formalise the partnership. The project focuses on

The approval covers patients aged 12 years and older with inhibitors, as well as children aged six to 11 years, with or without inhibitors. Hympavzi is approved for